There are several manufacturers of neratinib/neratinib

Neratinib/Neratinib (Neratinib) is a targeted drug for the treatment of breast cancer. Its supply on the market mainly depends on several major pharmaceutical manufacturers. The number of neratinib manufacturers may actually vary due to factors such as market changes, new drug research and development, and mergers and acquisitions of pharmaceutical companies.

Neratinib was discovered and initially developed by Wyeth; Pfizer continued to develop breast cancer until the third phase and licensed it to Puma Biotechnology in 2011. The company focuses on the development and commercialization of cancer treatment drugs, especially targeted therapy drugs for malignant tumors such as breast cancer. Neratinib is approved for the long-term adjuvant treatment of adult patients with early-stage hormone receptor-positive HER2+ breast cancer who completed adjuvant trastuzumab-based therapy less than a year ago. Clinical data show that neratinib significantly improves progression-free survival over the recommended 12-month total treatment course.

In addition, there are other pharmaceutical companies that may also produce generic versions of neratinib. These companies may be distributed around the world and supply this drug to the market through different channels, such as Bangladesh Beacon Pharmaceutical (HERNIX), Bangladesh Hertinib and so on.

As a prescription drug, the production and sale of neratinib is strictly regulated. Drug regulatory agencies in various countries and regions will strictly review and supervise pharmaceutical companies' production facilities, quality management systems, and the safety and effectiveness of drugs. Therefore, neratinib available on the market usually comes from certified and approved pharmaceutical manufacturers.